您的位置: 首页 > 农业专利 > 详情页

Способ лечения роговично-конъюнктивального ксероза
专利权人:
federalnoe gosudarstvennoe byudzhetnoe obrazovatelnoe uchrezhdenie vysshego obrazovaniya "Privolzhskij issledovatelskij meditsinskij universitet" Ministerstva zdravookhraneniya Rossijskoj Federatsii
发明人:
Stolyarova Valentina Vasilevna,Столярова Валентина Васильевна,Chekalova Natalya Genrikhovna,Чекалова Наталья Генриховна,Rudakova Galina Vasilevna,Рудакова Галина Васильевна,Zhdanovich Ilya Vladimirovi
申请号:
RU2017123484
公开号:
RU0002652581C1
申请日:
2017.07.03
申请国别(地区):
RU
年份:
2018
代理人:
摘要:
FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to ophthalmology and clinical pharmacology, and can be used to treat corneoconjunctival xerosis. Method comprises administering in the form of eye drops of medicinal substances in a certain mode. 1 drop of drug, containing active ingredients tobramycin and dexamethasone, administered in patient conjunctival eye bag 4 times a day for 24 days. Drug, containing the active substances dextran-70 and hypromelase, administered for 30 days. In the first 24 days, 1 drop 4–6 times a day and 1 drop 3 times a day in the last 6 days. On the 20th day after the beginning of treatment, the drug containing the active substance parahaminobenzoic acid is administered, 1 drop 2 times a day for 10 days. On the 25th day after the start of treatment, a drug containing active ingredients sodium hyaluronate and succinic acid administered 1–2 drops 2 times a day for 14 days and the preparation containing sodium hyaluronate, B-panthenol and sodium chondroitin sulfate 1–2 drops once a day for 14 days. In this case, the administration of the drugs is carried out 30 minutes after the administration of the preparation containing sodium hyaluronate, B-panthenol and sodium chondroitin sulfate. Time of administration between other drugs is from above 15–20 minutes.EFFECT: method stimulates the restoration of the structure of the epithelium of the conjunctiva and meibomian glands, which contributes to increased tear production, stability of the tear film, increases the thickness of the cornea and immunological resistance, does not lead to the thinning of the xerotically altered cornea.3 cl, 4 ex, 2 tblИзобретение относится к медицине, в частности к офтальмологии и клинической фармакологии, и может быть использовано для лечения роговично-конъюнктивального ксероза. Способ включает введение в виде глазных капель лекарственных веществ в определенном режиме. Препарат, содержащий действующие вещества тобрамицин и дексаметазон, вводят п
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充